DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: Cambrex High Point, Inc.

ACTION: Notice of application.

Dated: September 26, 2018.
Uttnam Dhillon,
Acting Administrator.

BILLING CODE 4410–09–P

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substance to the above listed company.

Dated: September 24, 2018.
John J. Martin,
Assistant Administrator.

BILLING CODE 4410–09–P

<table>
<thead>
<tr>
<th>Company</th>
<th>FR Docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galephar Pharmaceutical Research Inc</td>
<td>83 FR 37525</td>
<td>August 1, 2018</td>
</tr>
</tbody>
</table>

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application:Specgx, LLC

ACTION: Notice of registration.

SUMMARY: Registrant listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as an importer of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>1100</td>
<td>II</td>
</tr>
<tr>
<td>Codeine</td>
<td>9050</td>
<td>II</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>9652</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>9668</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to manufacture the above listed controlled substances in bulk for distribution to its customers.

Dated: October 1, 2018.
John J. Martin,
Assistant Administrator.

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Specgx, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before November 14, 2018. Such persons may also file a written request for a hearing on the application on or before November 14, 2018.

ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on July 16, 2018, Cambrex High Point Inc., 4180 Mendenhall Oaks Parkway, High Point, North Carolina 27265–8017 applied to be registered as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>1100</td>
<td>II</td>
</tr>
<tr>
<td>Codeine</td>
<td>9050</td>
<td>II</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>9652</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>9668</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to manufacture the above listed controlled substances in bulk for distribution to its customers.
The company plans to manufacture the above-listed controlled substance in gram quantities for sale as analytical research standards.

Dated: September 24, 2018.

John J. Martin,
Assistant Administrator.

FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–4129 (this is not a toll-free number) or by email at DOL_PRA_PUBLIC@dol.gov.

Submit comments about this request by mail to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL–OASP, Office of Management and Budget, Room 10235, 725 17th Street NW, Washington, DC 20503; by Fax: 202–395–5806 (this is not a toll-free number); or by email: OIRA_submission@omb.eop.gov. Commenters are encouraged, but not required, to send a courtesy copy of any comments by mail or courier to the U.S. Department of Labor–OASAM, Office of the Chief Information Officer, Attn: Departmental Information Compliance Management Program, Room N1301, 200 Constitution Avenue NW, Washington, DC 20210; or by email: DOL_PRA_PUBLIC@dol.gov.

This proposed information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public generally is not required to respond to an information collection, unless it is approved by the OMB under the PRA and displays a valid OMB Control Number. For additional information, see the related notice published in the Federal Register on July 12, 2017 (82 FR 32204). Interested parties are encouraged to send comments to the OMB, Office of Information and Regulatory Affairs at the address shown in the ADDRESSES section within thirty (30) days of publication of this notice in the Federal Register. In order to help ensure appropriate consideration, comments should mention OMB ICR Reference Number 201801–1290–001. The OMB is particularly interested in comments that:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated,